Insomnia (short-term treatment)

Brotizolam is a short-acting benzodiazepine with general properties similar to those of diazepam. It is given for the short-term (up to 2 weeks) management of insomnia.

Bioavailability:∼ 70%; Protein binding: 89%-95%; mainly metabolized in the liver, with hydroxylation in the 9-methyl and 6-positions; Elimination half-life is 3.1-8.4 hours in health subjects, but prolonged to 9.3hrs in elderly patients.

in patients with myasthenia gravis; severe respiratory insufficiency; sleep apnoea syndrome, patients with severe hepatic insufficiency; known hypersensitivity to brotizolam or to any of the ingredients in the formulation.

not recommended; may predispose to effects in the neonate such as hypothermia, hypotonia, and moderate respiratory depression.

not recommended

lightheadedness, fatigue, headache, drowsiness, decreased memory, confusion, depression; nausea vomiting, falling, GI pain, dry mouth

Adults: Oral: 0.25 mg at bedtime. The suggested dose for elderly and debilitated patients is 0.125 ;mg.